Welcome to chemicalbook!
400-158-6606
Try our best to find the right business for you.
Do not miss inquiry messages Please log in to view all inquiry messages.

Welcome back!

ChemicalBook > Product Catalogue >API >Respiratory Drugs >Asthma drugs >Montelukast sodium

Montelukast sodium

Montelukast sodium Structure
  • ₹5700 - ₹53334.78
  • Product name: Montelukast sodium
  • CAS: 151767-02-1
  • MF: C35H37ClNNaO3S
  • MW: 610.18
  • EINECS:604-813-7
  • MDL Number:MFCD00931431
  • Synonyms:montelucast-d6;Montelukast Soudium Tablets;Montelukast sodium ,99%;1-[1-[[[(1R)-1-[3-[(1E)-2-(7-Chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-Methylethyl)phenyl]propyl]thio]Methyl]cyclopropaneacetic Acid SodiuM Salt;Montelukast SoudiuM;MONTELUKST SODIUM;MONTELUKAST SODIUM;MK-476, Singulair
5 prices
Selected condition:

Brand

  • TCI Chemicals (India)
  • Sigma-Aldrich(India)

Package

  • 10MG
  • 50MG
  • 200MG
  • 1G
  • ManufacturerTCI Chemicals (India)
  • Product numberM2340
  • Product descriptionMontelukast Sodium
  • Packaging200MG
  • Price₹5700
  • Updated2022-05-26
  • Buy
  • ManufacturerTCI Chemicals (India)
  • Product numberM2340
  • Product descriptionMontelukast Sodium
  • Packaging1G
  • Price₹8100
  • Updated2022-05-26
  • Buy
  • ManufacturerSigma-Aldrich(India)
  • Product numberPHR1603
  • Product descriptionMontelukast Sodium Pharmaceutical Secondary Standard; Certified Reference Material
  • Packaging1G
  • Price₹12416.28
  • Updated2022-06-14
  • Buy
  • ManufacturerSigma-Aldrich(India)
  • Product numberSML0101
  • Product descriptionMontelukast sodium hydrate ≥98% (HPLC)
  • Packaging10MG
  • Price₹13228.15
  • Updated2022-06-14
  • Buy
  • ManufacturerSigma-Aldrich(India)
  • Product numberSML0101
  • Product descriptionMontelukast sodium hydrate ≥98% (HPLC)
  • Packaging50MG
  • Price₹53334.78
  • Updated2022-06-14
  • Buy
Manufacturer Product number Product description Packaging Price Updated Buy
TCI Chemicals (India) M2340 Montelukast Sodium 200MG ₹5700 2022-05-26 Buy
TCI Chemicals (India) M2340 Montelukast Sodium 1G ₹8100 2022-05-26 Buy
Sigma-Aldrich(India) PHR1603 Montelukast Sodium Pharmaceutical Secondary Standard; Certified Reference Material 1G ₹12416.28 2022-06-14 Buy
Sigma-Aldrich(India) SML0101 Montelukast sodium hydrate ≥98% (HPLC) 10MG ₹13228.15 2022-06-14 Buy
Sigma-Aldrich(India) SML0101 Montelukast sodium hydrate ≥98% (HPLC) 50MG ₹53334.78 2022-06-14 Buy

Properties

Melting point :115 °C(dec.)
storage temp. :2-8°C
solubility :DMSO: ≥8mg/mL at 60°C
form :powder
color :white to tan
optical activity :[α]/D +90 to +106° in methanol (c=1)
Merck :14,6258
BCS Class :1
Stability :Stable for 1 year from date of purchase as supplied. Solutions in DMSO, distilled water, or ethanol may be stored at -20°C for up to 1 month.
InChIKey :LBFBRXGCXUHRJY-HKHDRNBDSA-M

Safety Information

Symbol(GHS): GHS hazard pictogramsGHS hazard pictograms
Signal word: Danger
Hazard statements:
Code Hazard statements Hazard class Category Signal word Pictogram P-Codes
H318 Causes serious eye damage Serious eye damage/eye irritation Category 1 Danger GHS hazard pictograms P280, P305+P351+P338, P310
Precautionary statements:
P280 Wear protective gloves/protective clothing/eye protection/face protection.

Description

Montelukast was launched as Singulair in Mexico and Finland for the management of mild to moderate asthma inadequately controlled by inhaled corticosteroids and short-acting beta2-agonists. Montelukast can be obtained by an seven-step synthesis from 3-[2(E)-(7-chloroquinolin-2-yl)vinyl] benzaldehyde. Montelukast is a potent, selective and orally active antagonist of the CysLT1 (formerly called LTD4) receptor, thus blocking the effects of the cysteinyl leukotrienes LTC4, LTD4 and LTE4 on microvascular permeability and the activation of eosinophils. Montelukast represents the third molecule of this class which has been approved in asthma after pranlukast (1995) and zafirlukast (1996). Montelukast has been studied extensively in placebo-controlled clinical trials, in mildly or severe asthmatic patients challenged with LTD4 or exercise. A variety of acute bronchoconstricting challenges were inhibited or attenuated with all doses used. Montelukast demonstrated clinically significant improvements in the parameters of asthma control associated with an appreciable improvement in quality of life., reducing days with asthma exacerbations and allowing significant tapering of corticosteroids. Montelukast is well-tolerated and only needs to be administered once a day.

Related product price